Initial dose: 10 mg to 80 mg orally once a day.
The initial dosage of Lipitor recommended for this patient in the prevention of cardiovascular disease is 10 mg to 80 mg orally once a day. This medicine may be administered at any time of the day without regard for meals.
Dose adjustments should be made at intervals of 2 to 4 weeks.
Studies have demonstrated that treatment with atorvastatin is associated with significant reductions in the risk of cardiovascular endpoints and stroke in various patient populations for both primary and secondary prevention.
For primary prevention, atorvastatin treatment was effective in hypertensive patients with normal or mildly elevated cholesterol levels as well as in patients with type II diabetes. Patients had relatively low cholesterol levels at baseline in both trials; however, treatment with atorvastatin still resulted in significant reductions in cardiovascular outcomes and stroke.
For secondary prevention, intensive lipid lowering therapy with atorvastatin 80 mg/day was associated with significant incremental clinical benefit beyond therapy with 10 mg/day in patients with stable coronary heart disease. It was also shown to significantly reduce the risk of clinical outcomes in coronary heart disease patients versus usual medical care.
Emily Taylor, despite being reunited with her husband from prison, becomes severely depressed with emotional episodes and suicide attempts. Her psychiatrist, Jonathan Banks, after conferring with her previous doctor, eventually prescribes an experimental new medication called Ablixa. The plot thickens when the side effects of the drug lead to Emily killing her husband in a "sleepwalking" state. With Emily plea-bargained into mental hospital confinement and Dr. Banks' practice crumbling around him, the case seems closed. However, Dr. Banks cannot accept full responsibility and investigates to clear his name. What follows is a dark quest that threatens to tear what's left of his life apart even as he discovers the diabolical truth of this tragedy. Written by Kenneth Chisholm (kchishol@)
While atazanavir/ritonavir does reduce the lamotrigine plasma concentration, no adjustments to the recommended dose-escalation guidelines for LAMICTAL should be necessary solely based on the use of atazanavir/ritonavir. Dose escalation should follow the recommended guidelines for initiating adjunctive therapy with LAMICTAL based on concomitant AED or other concomitant medications (see Tables 1, 2, and 5). In patients already taking maintenance doses of LAMICTAL and not taking glucuronidation inducers, the dose of LAMICTAL may need to be increased if atazanavir/ritonavir is added, or decreased if atazanavir/ritonavir is discontinued [see CLINICAL PHARMACOLOGY ].